Nóra Frank

Dr. Nóra Frank


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2022 in Orvosi Hetilap
Verified
Journal Article
Open access
PDF file
NFNóra Frank
Nóra Frank
ÁCÁgnes Csikós
Ágnes Csikós
Összefoglaló. A palliatív ellátás célja a beteg és családja életminőségének javítása egy életet megrövidítő betegség során. A palliatív betegpopuláció 32–80%-a kap szisztémás szteroidot kínzó tünetek enyhítésére. Az alkalmazási irányelvek, a szteroidhasználat a palliatív betegek körében nagyon változó az egyes országok, de az országon belüli ellátók között is. A palliatív betegellátásban szteroidokat – elsősorban szisztémás glükokortikoidokat (dexametazon, betametazon, prednizolon, metilprednizolon) – főleg antiinflammatorikus és a vascularis permeabilitást csökkentő hatásuk miatt alkalmazunk. A palliatív ellátás során glükokortikoid adása számos specifikus indikáció esetén javasolható, mint idegi kompresszió, neuropathiás fájdalom, csontfájdalom és metastasis, májtokfeszülés okozta fájdalom, malignus bélobstrukció, agynyomás-fokozódás, malignus gerincvelő-kompresszió, vena cava superior szindróma, lymphangitis carcinomatosa, nagy légúti obstrukció. Sokszor párhuzamosan jelentkező, nem specifikus tünetek – mint anorexia-cachexia szindróma, hányinger, hányás, fáradtság, gyengeség, nehézlégzés – szintén szükségessé tehetik szteroid adását. A palliatív betegek prognózisát figyelembe véve a szteroidok késői mellékhatásai nem korlátozzák adásukat, az elsődleges terápiás előny felülmúlja a lehetséges kockázatokat. A nemzetközi gyakorlatban a dexametazon a leggyakrabban alkalmazott glükokortikoid, kifejezett gyulladáscsökkentő hatása és kevesebb mineralokortikoid-mellékhatása miatt. Fontos, elengedhetetlen része a biztonságos szteroidterápiának a mellékhatások gondos monitorozása, erről a beteget és a hozzátartozókat is fel kell világosítani. A megfelelő indikációban, dózisban és megfelelő kezelési terv alapján adagolt szteroid hasznos része a palliatív tünetkontrollnak, a beteg életminőség-javításának. Orv Hetil. 2022; 163(8): 294–300. Summary. Palliative care aims to improve the quality of life of patients and their families during a life-shortening illness. 32–80% of the palliative patient population receive systemic steroids to relieve torturous symptoms during end-of-life care. Guidelines for steroid use among palliative patients vary widely from country to country, but also within providers. In palliative care, steroids – mainly systemic glucocorticoids (dexamethasone, betamethasone, prednisolone, methylprednisolone) – are used especially for their anti-inflammatory and vascular permeability-reducing effects. Glucocorticoid administration during palliative care is recommended for a number of specific indications, such as neural compression, neuropathic pain, bone pain and metastasis, liver capsule pain, malignant intestinal obstruction, increased cerebral pressure, malignant spinal cord compression, superior vena cava syndrome, carcinomatous lymphangitis, and large airway compression. Often concomitant non-specific symptoms such as anorexia-cachexia syndrome, nausea, vomiting, fatigue, weakness, dyspnoea may also necessitate steroid administration. Considering the prognosis of palliative patients, the late side effects of steroids do not limit their administration, the primary therapeutic benefit outweighs the potential risks. Internationally, dexamethasone is the most commonly used glucocorticoid due to its pronounced anti-inflammatory effect and fewer mineralocorticoid side effects. Careful monitoring of side effects is an important and essential part of safe steroid therapy and should be made clear to the patient and their relatives. Steroids administered in the right indication and dose as well as according to an appropriate treatment plan are useful parts of palliative symptom control and improve patients’ quality of life. Orv Hetil. 2022; 163(8): 294–300.

Verified
Journal Article
Open access
PDF file
NFNóra Frank
Nóra Frank
CBCsilla Busa
Csilla Busa
ESEszter Sághy
Eszter Sághy
EPEva Pozsgai
Eva Pozsgai
CÁCsikós Ágnes
Csikós Ágnes
Background: Outpatient palliative care effectively alleviates symptom burden in advanced cancer patients, yet data from Central–Eastern Europe remain scarce. This retrospective study examined changes in revised Edmonton Symptom Assessment Scale (ESAS) scores from initial outpatient palliative consultation to first follow-up in Hungarian cancer patients, assessing clinically meaningful improvement and inter-symptom associations. Methods: Revised ESAS scores from 119 patients attending an outpatient palliative care clinic (2017–2020) were analyzed using paired baseline and first follow-up assessments (7–30 days). Symptom changes (Time 2–Time 1) were evaluated using Wilcoxon signed-rank tests. Clinically meaningful improvement was assessed with minimal clinically important difference thresholds (0.5× baseline SD). Sankey diagrams visualized symptom transitions, and multivariable linear regression examined inter-symptom associations. Results: Baseline pain was highest (mean 6.29, median 7), followed by fatigue, sleep disorder, and impaired well-being. At follow-up, significant reductions were observed in pain (mean 4.52, p = 0.001), nausea, dyspnea, constipation, sleep disorder, depression, and anxiety (all p < 0.05). Sankey diagrams showed shifts from severe to mild/moderate pain (50% to 24%) and constipation. Clinically meaningful improvement occurred in pain, nausea, and constipation, with 59–65% achieving ≥1-point pain reduction. Regression analyses showed that pain reduction was associated with concurrent improvements in sleep disorder (β = 0.31), depression (β = 0.20), fatigue (β = 0.20), and anxiety (β = 0.14), while dyspnea reduction was associated with concurrent improvements in depression (β = 0.22) and anxiety (β = 0.14). Conclusions: Outpatient palliative care in Hungarian cancer patients resulted in clinically meaningful symptom reductions, particularly pain and dyspnea. Improvements in these core symptoms were associated with concurrent improvements in other symptom domains, underscoring the clinical relevance of inter-symptom associations and supporting early, integrated outpatient palliative care and symptom cluster-based management.